CHEVELLE PARKER: Open Payments
NPI 1922348465 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,160 in 16 payments from 8 companies in 2025. Trend: 2023 $762 · 2024 $692 · 2025 $1,160
Food & beverage: $1,160
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 2 | $263 |
| Corcept Therapeutics | 3 | $253 |
| BETA BIONICS, INC. | 5 | $238 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $120 |
| Lilly USA, LLC | 1 | $115 |
| Dexcom, Inc. | 1 | $104 |
| Medtronic, Inc. | 2 | $50 |
| AstraZeneca Pharmaceuticals LP | 1 | $17 |
Products named: Omnipod, Korlym, iLet Bionic Pancreas, Kerendia, ZEPBOUND, Dexcom G6 Transmitter, MINIMED 780G, FARXIGA.
Industry payments across LA — which companies pay providers there.
